LPCN - Lipocine Inc.

NasdaqCM - NasdaqCM Real Time Price. Currency in USD
1.335
-0.055 (-3.96%)
At close: 4:00PM EDT
Stock chart is not supported by your current browser
Previous Close1.390
Open1.390
Bid1.080 x 3100
Ask1.440 x 1200
Day's Range1.310 - 1.400
52 Week Range1.030 - 5.330
Volume54,965
Avg. Volume266,211
Market Cap28.388M
Beta-0.43
PE Ratio (TTM)N/A
EPS (TTM)-0.916
Earnings DateAug 6, 2018 - Aug 10, 2018
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est8.90
Trade prices are not sourced from all markets
  • ACCESSWIRE16 hours ago

    Free Research Reports on Ironwood Pharma and Three More Generic Drugs Stocks

    LONDON, UK / ACCESSWIRE / June 18, 2018/ If you want a free Stock Review on IRWD sign up now at www.wallstequities.com/registration. In today's pre-market research, WallStEquities.com observes the recent performance of Horizon Pharma PLC (NASDAQ: HZNP), Ironwood Pharmaceuticals Inc. (NASDAQ: IRWD), Lipocine Inc. (NASDAQ: LPCN), and Supernus Pharmaceuticals Inc. (NASDAQ: SUPN).

  • PR Newswire12 days ago

    Lipocine Announces Dosing in Ambulatory Blood Pressure Study for TLANDO™

    SALT LAKE CITY, June 7, 2018 /PRNewswire/ -- Lipocine Inc. (LPCN), a specialty pharmaceutical company, today announced the dosing of the first subject in the ambulatory blood pressure ("ABPM") clinical study for TLANDO™, the Company's oral testosterone product candidate for testosterone replacement therapy ("TRT") in adult males for conditions associated with a deficiency of endogenous testosterone, also known as hypogonadism.  This study was initiated after receiving FDA feedback on the ABPM clinical study protocol and is being conducted to definitively characterize TLANDO's blood pressure effect, if any.

  • Analysts Expect Breakeven For Lipocine Inc (NASDAQ:LPCN)
    Simply Wall St.last month

    Analysts Expect Breakeven For Lipocine Inc (NASDAQ:LPCN)

    Lipocine Inc’s (NASDAQ:LPCN): Lipocine Inc., a specialty pharmaceutical company, focuses on the development of pharmaceutical products in the area of men’s and women’s health. With the latest financial year lossRead More...

  • Zacks Small Cap Researchlast month

    LPCN: Another CRL: Updated Timeline Points to 1Q:19 FDA Response

    Lipocine Inc. (LPCN) received a complete response letter (CRL) from the FDA on May 8, 2017 which identified four deficiencies related to the New Drug Application submitted for Tlando, an oral testosterone product for testosterone replacement therapy. Additionally, the company will also schedule a Type A meeting with the FDA in response to the CRL for further guidance on how to proceed.

  • ACCESSWIRElast month

    Free Daily Technical Summary Reports on Horizon Pharma and Three More Generic Drugs Stocks

    LONDON, UK / ACCESSWIRE / May 11, 2018 / If you want a free Stock Review on HZNP sign up now at www.wallstequities.com/registration. WallStEquities.com features the Generic Drugs market, which can be segmented into biosimilars, simple generic, and super generic. The market for generic drugs is based on the premise that patented drugs come with a lifespan of 20 years, which begins from the phase of clinical trials.

  • Benzingalast month

    Lipocine's Regulatory Hiccups Continue: Testosterone Drug Issued Complete Response Letter, Stock Tanks

    Lipocine Inc (NASDAQ: LPCN) stock is poised to lose about one-third of its market value Wednesday, as its Tlando was handed a complete response letter from the FDA for a second time. Lipocine announced Wednesday ahead of the market open the FDA issued a CRL for its new drug application for Tlando, its testosterone replacement therapy intended to treat hypogonadism. A CRL is a communication from the FDA that an application cannot be approved in its present form.

  • Benzingalast month

    Benzinga Pro's 5 Stocks To Watch Today

    Each day, the Benzinga Pro news team highlights several stocks with Trading Idea potential. Be the first to see them by becoming a Benzinga Pro user ! Walmart Inc (NYSE: WMT ) stock was trading lower by ...

  • MarketWatchlast month

    Lipocine shares drop 38% after FDA fails to approve testosterone replacement therapy

    Lipocine Inc. shares dropped 38% in premarket trade on Wednesday after the Food and Drug Administration failed to approve its testosterone replacement therapy. The product, Tlando, is the furthest along of Lipocine's three drug candidates. The FDA identified four deficiencies with Tlando's new drug application that affected its ability to approve it, Lipocine said.

  • PR Newswirelast month

    Lipocine Receives Complete Response Letter for TLANDO From U.S. Food and Drug Administration

    SALT LAKE CITY, May 9, 2018 /PRNewswire/ -- Lipocine Inc. (LPCN), a specialty pharmaceutical company, announced today that it has received a Complete Response Letter ("CRL") from the United States Food and Drug Administration ("FDA") regarding its New Drug Application ("NDA") for TLANDO™, the Company's oral testosterone product candidate for testosterone replacement therapy ("TRT") in adult males for conditions associated with a deficiency of endogenous testosterone, also known as hypogonadism. A CRL is a communication from the FDA that informs companies that an application cannot be approved in its present form.

  • Benzingalast month

    Benzinga's Daily Biotech Pulse: Valeant Earnings, Lipocine's FDA Watch, Invivo CFO Departure

    Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling the Peaks (Stocks hitting 52-week highs on May 7) Boston Scientific Corporation (NYSE: BSX ) DexCom, Inc. (NASDAQ: ...

  • Associated Presslast month

    Lipocine: 1Q Earnings Snapshot

    On a per-share basis, the Salt Lake City-based company said it had a loss of 13 cents. The specialty pharmaceutical company posted revenue of $428,000 in the period. The company's shares closed at $1.54. ...

  • PR Newswirelast month

    Lipocine Announces Financial and Operational Results for the First Quarter Ended March 31, 2018

    SALT LAKE CITY , May 7, 2018 /PRNewswire/ --  Lipocine Inc. (NASDAQ: LPCN), a specialty pharmaceutical company, today announced financial results for the first quarter ended March 31, 2018 . First Quarter ...

  • GlobeNewswire2 months ago

    Pomerantz LLP Announces Proposed Class Action Settlement on Behalf of Purchasers of Securities of Lipocine, Inc. -- LPCN

    SALT LAKE CITY, April 23, 2018-- Pomerantz LLP announces that the United States District Court for the District of Utah has approved the following announcement of a proposed class action settlement that ...

  • ACCESSWIRE2 months ago

    Free Research Report as Lipocine Announced FY17 Financial Results

    Stock Monitor: MYOS RENS Technology Post Earnings Reporting LONDON, UK / ACCESSWIRE / April 20, 2018 / Active-Investors.com has just released a free earnings report on Lipocine Inc. (NASDAQ: LPCN ). If ...

  • Zacks Small Cap Research3 months ago

    LPCN: Coming at the FDA Like a Spider Monkey

    Lipocine Inc. (LPCN) filed its 2017 10-K and posted its earnings release on March 12, summarizing an volatile year which included new dosing studies for Tlando and a resubmission of the drug to the FDA. Several key events have taken place year to date with additional financing secured and an advisory committee meeting that sought additional information for the company’s testosterone replacement therapy product. Progress was also made on patent rights and class action lawsuits, placing Lipocine in a stronger position overall with respect to Clarus’ patent.

  • PR Newswire3 months ago

    Lipocine to Present at the 17th Annual Needham Healthcare Conference

    SALT LAKE CITY , March 21, 2018 /PRNewswire/ --  Lipocine Inc. (NASDAQ: LPCN), a specialty pharmaceutical company, announced today that Dr. Mahesh Patel , Chairman, President and CEO, will provide a corporate ...

  • PR Newswire3 months ago

    Lipocine to Present at the Oppenheimer 28th Annual Healthcare Conference

    SALT LAKE CITY , March 14, 2018 /PRNewswire/ --  Lipocine Inc. (NASDAQ: LPCN), a specialty pharmaceutical company, announced today that Dr. Mahesh Patel , Chairman, President and CEO, will provide a corporate ...

  • PR Newswire3 months ago

    Lipocine Announces Financial and Operational Results for the Fiscal Year Ended December 31, 2017

    SALT LAKE CITY , March 12, 2018 /PRNewswire/ -- Lipocine Inc. (NASDAQ: LPCN), a specialty pharmaceutical company, today announced financial results for the fourth quarter and fiscal year ended December ...

  • Interested In Lipocine Inc (NASDAQ:LPCN)? Here’s What Its Recent Performance Looks Like
    Simply Wall St.3 months ago

    Interested In Lipocine Inc (NASDAQ:LPCN)? Here’s What Its Recent Performance Looks Like

    For investors with a long-term horizon, assessing earnings trend over time and against industry benchmarks is more valuable than looking at a single earnings announcement in one point in time.Read More...

  • PR Newswire3 months ago

    Lipocine to Present at the 30th Annual ROTH Conference

    SALT LAKE CITY , March 5, 2018 /PRNewswire/ --  Lipocine Inc. (NASDAQ: LPCN), a specialty pharmaceutical company, announced today that Dr. Mahesh Patel , Chairman, President and Chief Executive Officer, ...

  • Business Wire4 months ago

    LIPOCINE INVESTIGATION INITIATED by Former Louisiana Attorney General: Kahn Swick & Foti, LLC Investigates the Officers and Directors of Lipocine Inc. – LPCN

    Former Attorney General of Louisiana, Charles C. Foti, Jr., Esq., a partner at the law firm of Kahn Swick & Foti, LLC , announces that KSF has commenced an investigation into Lipocine Inc.

  • ACCESSWIRE4 months ago

    Today’s Research Reports on Stocks to Watch: Lipocine and DelMar Pharmaceuticals

    NEW YORK, NY / ACCESSWIRE / February 28, 2018 / Lipocine shares were on fire after receiving an upgrade and a price target of $21 a share. Shares of DelMar Pharmaceuticals also soared higher despite any ...

  • Benzinga4 months ago

    Empire Asset Assigns Penny Stock Lipocine $21 Price Target, Buy Rating

    Lipocine Inc (NASDAQ: LPCN ) is still down 57 percent since the U.S. Food and Drug Administration’s Bone, Reproductive and Urologic Drugs Advisory Committee voted 6-13 on Tlando’s benefit-risk profile. ...

  • LIPOCINE INVESTIGATION INITIATED BY FORMER LOUISIANA ATTORNEY GENERAL: Kahn Swick & Foti, LLC Investigates the Officers and Directors of Lipocine Inc. - LPCN
    PR Newswire4 months ago

    LIPOCINE INVESTIGATION INITIATED BY FORMER LOUISIANA ATTORNEY GENERAL: Kahn Swick & Foti, LLC Investigates the Officers and Directors of Lipocine Inc. - LPCN

    NEW ORLEANS , Feb. 16, 2018 /PRNewswire/ -- Former Attorney General of Louisiana , Charles C. Foti, Jr., Esq. , a partner at the law firm of Kahn Swick & Foti, LLC ("KSF"), announces that KSF ...

  • PR Newswire4 months ago

    Lipocine Announces Settlement of Securities Class Action Lawsuit

    SALT LAKE CITY, Feb. 16, 2018 /PRNewswire/ -- Lipocine Inc. (LPCN), a specialty pharmaceutical company, announced today that the Company and the other defendants have entered into a memorandum of understanding to settle the purported securities class action litigation captioned In re Lipocine Inc. Securities Litigation, 2:17CV00182 DB (D. Utah). The memorandum of understanding contemplates that the parties will enter into a settlement agreement, which, if entered into, will be subject to customary conditions including court approval following notice to the stockholders of the Company, and a hearing at which time the court will consider the fairness, reasonableness and adequacy of the settlement.  If a settlement is finally approved by the court, it will resolve all of the claims that were or could have been brought in the action being settled.